Dr. Heimberger on the Variability of Responses in Glioblastoma
Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.
Dr. Heimberger on FGL2 as a Regulator of Tumor-Mediated Immune Suppression
Amy B. Heimberger, MD, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma.
Immunotherapy Must Become More Precise and Personalized in Lung Cancer
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
2 Clarke Drive Cranbury, NJ 08512